By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Elusys Therapeutics, Inc. 

25 Riverside Drive
P.O. Box 102
Pine Brook  New Jersey  07058  U.S.A.
Phone: 973-808-0222 Fax: 973-808-0322



Company News
Elusys Therapeutics, Inc. Release: U.S. FDA Accepts Biologics License Application For Anthim (Obiltoxaximab) 6/1/2015 10:40:47 AM
Elusys Therapeutics, Inc. Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 9/22/2014 10:39:54 AM
Elusys Therapeutics, Inc. Completes Commercial Manufacturing Process Validation For Anthrax Antitoxin ETI-204 4/9/2014 8:38:10 AM
Elusys Therapeutics, Inc. Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, ETI-204, In Adult Volunteers 2/5/2014 8:20:07 AM
Elusys Therapeutics, Inc. Releases New Data on Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies 8/1/2013 8:58:55 AM
Alliance for Biosecurity Elects Chief Executive Officers of Bavarian Nordic (BAVA.CO) and Elusys Therapeutics, Inc. as New Co-Chairs 7/1/2013 8:17:59 AM
Elusys Therapeutics, Inc. Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax 9/17/2012 10:01:20 AM
Elusys Therapeutics, Inc. Receives Additional $14.5 Million Funding From U.S. Govt. to Support Expanded Human Safety Studies of ETI-204 9/17/2012 7:12:49 AM
Elusys Therapeutics, Inc. Gets $50.2 Million to Advance Investigational Anthrax Treatment 8/3/2012 8:05:55 AM
Elusys Therapeutics, Inc. Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale 10/24/2011 2:27:09 PM